History of hemoptysis within the last 1 month
Patients must not have had hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months prior registration
Patients who have had recent hemoptysis (>= 1/2 teaspoon of red blood within 8 weeks before first dose of study drug) are NOT eligible for participation
Evidence of active bleeding or bleeding diathesis; recent hemoptysis (>= 1/2 teaspoon of red blood within 8 weeks before first dose of study drug)
Evidence of active bleeding or bleeding diathesis; recent hemoptysis (>= ½ teaspoon of red blood within 8 weeks before first dose of study drug)
Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
Evidence of hemoptysis within the last 7 days.
History of hemoptysis within the last 1 month prior to randomization
History of hemoptysis or any significant bleeding within the last 1 month prior to enrollment
Pulmonary hemorrhage or hemoptysis > 2.5 mL blood within 6 weeks (or within 2 weeks if source definitively treated [eg, radiation therapy or bronchoscopic procedure])
History of known hemoptysis, gastrointestinal or intracerebral hemorrhage
Patients with active hemoptysis
Clinically significant hematemesis or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (such as pulmonary hemorrhage) within 4 weeks of enrollment
Recent hemoptysis (>= 1/2 teaspoon of red blood within 8 weeks before first dose of pazopanib)
Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug
Pulmonary hemorrhage or hemoptysis > 2.5 ml blood within 6 weeks unless cause has been addressed and is medically resolved.
Patients with hemoptysis in excess of 2.5 mL within 6 weeks prior to the first dose of study medication
Active hemoptysis within 1 week of screening (more than 1/2 teaspoon per day)
No hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 12 weeks before the first dose of study treatment
Patient must not have had clinically significant hemoptysis, defined as greater than 1 tablespoon of bright red blood, within one year prior to registration; although hemoptysis has not been associated with cediranib, it may be a class effect for anti-angiogenic agents and therefore a risk factor for this experimental agent
History of hemoptysis in excess of 2.5 mL (1/2 teaspoon) within 8 weeks prior to first dose of pazopanib
Patient must not have history of hemoptysis in excess of 2.5 mL (1/2 teaspoon) within 8 weeks prior to randomization
Recent hemoptysis (>= 1/2 teaspoon of red blood within 8 weeks before first dose of pazopanib)
Clinically significant hemoptysis or tumor bleeding within two weeks prior to first dose of lenvatinib.
History of hemoptysis of ? 2.5 mL/1 teaspoon within 6 months of Cycle 1 Day 1
Has hemoptysis within 6 weeks prior to randomization.
Recent hemoptysis
Hemoptysis >1 teaspoon in 24 hours within the last 28 days.
History of pulmonary hemorrhage or hemoptysis within 6 months of starting study treatment
Hemoptysis >1 teaspoon in 24 hours within the last 28 days.
Hemoptysis (defined as > ½ teaspoon of blood)
Recent hemoptysis (>= 1/2 teaspoon [2.5 mL]) of red blood within 8 weeks before first dose of study drug
Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to first dose of lenvatinib
Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug
No evidence of active bleeding, bleeding diathesis, or hemoptysis (>= 1/2 teaspoon of red blood) within 8 weeks prior to registration
Recent hemoptysis (>= ½ teaspoon of red blood within 8 weeks before first dose of study drug)
Grade 3 or 4 hemoptysis or hemorrhage within 4 weeks prior to study entry
Patient must not experience hemoptysis in excess of 2.5 mL within 8 weeks prior to the first dose of pazopanib
Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of registration
History of hemoptysis in excess of 2.5 mL (1/2 teaspoon ) within 8 weeks prior to first dose of study drug
History of hemoptysis
Hemoptysis within 6 weeks of first dose of study drug
EXPANSION COHORT ONLY: Hemoptysis within 6 weeks of first dose of study drug
Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
Patients with active bleeding, including hemoptysis within 4 weeks of enrollment should be excluded, as there is no safety data with vorinostat in this setting
Hemoptysis within 4 weeks
Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks prior to first dose of study drug
Hemoptysis of red blood in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug.
Baseline hemoptysis, per clinician/investigator evaluation
Presence or history of hemoptysis (>1/2 teaspoon of red blood) 2 weeks prior to the first dose of GSK3052230
Hemoptysis in excess of 2.5 mL within 8 weeks of first dose of study drug.
Active hemoptysis
Hemoptysis within 6 weeks of first dose of study drug
Recent hemoptysis (>= ½ teaspoon of red blood within 8 weeks before first dose of study drug)
Recent hemoptysis (>= half teaspoon of red blood within 8 weeks before first dose of study drug)
No evidence of active bleeding, bleeding diathesis, or hemoptysis (>= ½ teaspoon of red blood) within 8 weeks of registration
Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
Active hemoptysis or history of clinically relevant hemoptysis as determined by the treating physician; patients who had history of transient minor hemoptysis after bronchoscopic biopsy are eligible unless deemed otherwise by the treating physician
Pulmonary hemorrhage or hemoptysis > 2.5 mL blood within six weeks unless cause has been addressed and is medically resolved
Patient must not have hemoptysis within 6 weeks of first dose of study drug
Patients must not demonstrate any other signs indicative of pulmonary hemorrhage within 3 months prior to registration
The subject has experienced any of the following:\r\n* Clinically-significant GI bleeding within 6 months before the first dose of cabozantinib\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of cabozantinib\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of cabozantinib
The subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal (GI) bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The participant has experienced any of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The subject has experienced any of the following: a. clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment; b. hemoptysis >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment; c. any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment. Tumor invading any major blood vessel at the time of study enrollment.
The subject has experienced any of the following:\r\n* Clinically significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Clinically significant hemoptysis within 3 months of the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the start of study treatment
The subject has any of the following risks of bleeding:\r\n* Clinically-significant gastrointestinal (GI) bleeding within 6 months before enrollment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months enrollment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before enrollment\r\n* Radiographic evidence of cavitating pulmonary lesion(s)
The subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal (GI) bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of study treatment\r\n* any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment; and\r\n* Clinically confirmed history of interstitial lung disease (ILD)
The subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment\r\n* The subject has radiographic evidence of cavitating pulmonary lesion(s); chest x-ray will not be required as part of this trial, unless cavitating pulmonary lesion is clinically suspected
The subject has experienced any of the following: \r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment; \r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment; \r\n* Any other signs indicative of hemorrhage within 3 months before the first dose of study treatment
The subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The subject has experienced any of the following: a. clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment, b. hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of study treatment, c. any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5ml) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The subject has experienced any of the following:\r\n* Clinically-significant GI bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The subject has experienced clinically-significant hematemesis or hemoptysis of > 0.5 teaspoon of red blood, or other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The subject has experienced any of the following within 3 months before the first dose of\r\nstudy treatment:\r\n* Clinically-significant hematemesis or lower gastrointestinal bleeding\r\n* Hemoptysis of > 0.5 teaspoon of red blood\r\n* Any other signs indicative of pulmonary hemorrhage
No signs indicative of pulmonary hemorrhage within 12 weeks before the first dose of study treatment
Previously experienced any of the following:\r\n* Clinically significant gastrointestinal bleeding within 6 months\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within the last 3 months\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months
Previously experienced any of the following:\r\n* Clinically significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The subject has experienced any of the following within 3 months before the first dose of study treatment:\r\n* Clinically-significant hematemesis or gastrointestinal bleeding\r\n* Hemoptysis of >= 0.5 teaspoon (>= 2.5 mL) of red blood\r\n* Any other signs indicative of pulmonary hemorrhage
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving (in contact with, invading or encasing) major vessels; patients who have experienced any of the following:\r\n* Clinically significant gastrointestinal bleeding within 6 months before first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The subject has experienced any of the following:\r\n* Clinically-significant hematemesis or gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The participant has experienced any of the following within 3 months before the first dose of study treatment:\r\n* Clinically-significant hematemesis or lower gastrointestinal bleeding\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood\r\n* Any other signs indicative of pulmonary hemorrhage
The subject has a history of clinically significant hematemesis or a recent history of hemoptysis of > 2.5 mL of red blood or other signs indicative of pulmonary hemorrhage or evidence of endobronchial lesion(s)
The subject has experienced any of the following:\r\n* Clinically significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
Subject has had clinically-significant hematemesis or hemoptysis of > 0.5 teaspoon of red blood, or other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The subject has experienced any of the following within 6 months before the first dose of study treatment:\r\n* Clinically significant hematemesis or gastrointestinal bleeding\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood\r\n* Any other signs indicative of pulmonary hemorrhage
The subject has experienced any of the following\r\n* Clinically-significant gastrointestinal bleeding within 3 months before the first dose of study treatment; the participant must be maintained on a prophylactic regimen for management of an upper gastrointestinal (GI) bleeding event with no evidence of recurrence and/or endoscopic confirmation of resolution of the source of a lower GI bleed\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
The subject has experienced any of the following within 3 months before the first dose of study treatment:\r\n* Clinically-significant hematemesis or gastrointestinal bleeding\r\n* Clinically-significant hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood\r\n* Any other signs indicative of pulmonary hemorrhage
Hemoptysis (> ½ teaspoon [2.5 mL] of bright red blood) within 6 months prior to randomization
Severe, active co-morbidity defined as follows:\r\n* Current (within 28 days of cycle 1, day 1) signs and/or symptoms of bowel obstruction\r\n* Patients who require parental hydration and/or nutrition\r\n* Patients who require drainage gastrostomy tube\r\n* Evidence of bleeding diathesis or clinically significant coagulopathy\r\n* Serious, non-healing or dehiscing wound, active ulcer or untreated bone fracture\r\n* History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment
History of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months of starting study treatment
Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug
Pulmonary hemorrhage or gross hemoptysis (bright red blood of >= 1/2 teaspoon per episode) within 6 months prior to enrollment
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1
Patients with history of hematemesis or hemoptysis (defined as having bright red blood of 1/2 teaspoon or more per episode) within 28 days prior to registration
History of pulmonary hemorrhage/hemoptysis >= grade 2 (defined as >= 2.5 mL bright red blood per episode) within 1 month prior to randomization.
History of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months prior to study treatment
(Bevacizumab-related exclusion) History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment for any tumor type
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) =< 28 days of study enrollment
History of hemoptysis (defined as > 1/2 tablespoon [tsp] of bright red blood per day)
Patients with hemoptysis (defined as bright red blood or >= 1/2 teaspoon) within 2 months prior to enrollment, or with central or cavitating lesions, will be excluded
History of pulmonary hemorrhage/hemoptysis >= grade 2 (defined as >= 2.5 mL bright red blood per episode) within 1 month prior to on-study date
Gastrointestinal bleeding or active hemoptysis (bright red blood of at least half teaspoon) within 3 weeks prior to the first dose of study drug.
History of hemorrhage or hemoptysis (> 1/2 teaspoon bright red blood) within 3 months of starting study treatment
History of hemoptysis ( >= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1 of FOLFIRI + bevacizumab initiation
Active hemoptysis (bright red blood of at least 0.5 teaspoon) or tumor bleeding within 3 weeks prior to the first dose of study drug
History of hemoptysis (? 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1
History of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months of starting study treatment
No active or recent hemoptysis (>= 1/2 teaspoon of bright red blood per episode) =< 30 days prior to registration
Patients are excluded if they have a history of hemoptysis (bright red blood of 1/2 teaspoon or more per episode) within 3 months prior to randomization
History of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months of starting study treatment
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment for any tumor type
Active hemoptysis (bright red blood of at least 2.5 mL ie, half teaspoon) within 3 weeks prior to the first dose of study drug.
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) or other significant spontaneous bleeding event within 1 month prior to day 1 of study drug or at any time on a prior VEGF inhibitor
Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5 teaspoon) within 28 days prior to randomization
Have a significant bleeding disorder or vasculitis or had a Grade ?3 bleeding episode within 12 weeks prior to enrollment. Participants with a history of gross hemoptysis (defined as bright red blood of ?1/2 teaspoon) within 2 months prior to enrollment are excluded.
Active or recent history of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) =< 30 days prior to registration/randomization
Gastrointestinal bleeding or active hemoptysis (bright red blood of at least half teaspoon) within 21 days prior to enrollment
Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks before the first dose of study drug.
History of hemoptysis (1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1.
No history of gross hemoptysis (defined as bright red blood of a half-teaspoon or more) within 3 months prior to enrollment
History of hemoptysis >= grade 2 (defined as bright red blood of at least 2.5 mL) =< 3 months prior to randomization
History of gastrointestinal (GI) bleeding (hemoptysis/melena/hematochezia, >= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day -3
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1
History of uncontrolled hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1
History of hemoptysis (greater than or equal to 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1
History of hemoptysis ( >= 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1
History of hemoptysis (>/=1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1.
History of/or current evidence of hemoptysis (bright red blood of ½ teaspoon or more)
History of hemoptysis (? 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1
Patients with a history of gross hemoptysis (defined as bright red blood of ½ teaspoon or more) will be excluded from this trial
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1
History of hemoptysis (>= ½ teaspoon of bright red blood per episode) within 1 month prior to day 1
History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1
Active hemoptysis (bright red blood > 1 teaspoon on more than one occasion) =< 3 weeks prior to registration
Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.
